124 Matching Annotations
  1. Apr 2021
  2. Mar 2021
    1. Rosendaal, F. R. (2020). Review of: “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949. International Journal of Antimicrobial Agents, 106063. https://doi.org/10.1016/j.ijantimicag.2020.106063

    1. Yufika, A., Wagner, A. L., Nawawi, Y., Wahyuniati, N., Anwar, S., Yusri, F., Haryanti, N., Wijayanti, N. P., Rizal, R., Fitriani, D., Maulida, N. F., Syahriza, M., Ikram, I., Fandoko, T. P., Syahadah, M., Asrizal, F. W., Aletta, A., Haryanto, S., Jamil, K. F., … Harapan, H. (2020). Parents’ hesitancy towards vaccination in Indonesia: A cross-sectional study in Indonesia. Vaccine, 38(11), 2592–2599. https://doi.org/10.1016/j.vaccine.2020.01.072

    1. Meng Z , Wang T , Li C  et al.   PREPRINT: An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area. medRxiv  2020:2020.04.11.20061473. doi:10.1101/2020.04.11.20061473.
    1. Meng Z , Wang T , Li C  et al.   PREPRINT: An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area. medRxiv  2020:2020.04.11.20061473.
  3. Feb 2021
    1. Dr Ellie Murray. (2020, December 3). Some really great resources & discussions in this thread. The tl;dr is (1) yes, the vaccine trials included some people who had previously had COVID; and (2) in general vaccination plans will include those who have previously been sick/infected. Thanks all! [Tweet]. @EpiEllie. https://twitter.com/EpiEllie/status/1334545373126389766

    1. Carl T. Bergstrom. (2020, December 5). I don’t have a background in medical ethics but this makes me uncomfortable unless it was very clearly explained to study participants at enrollment, and to some degree even then. H/t @RMCarpiano https://t.co/WUE1mXgjJG https://t.co/yLXkxIa5O8 [Tweet]. @CT_Bergstrom. https://twitter.com/CT_Bergstrom/status/1335152266840424449

    1. Eric Topol. (2021, February 17). New reports @NEJM today confirming some immune evasion of the B.1.351 variant (identified in South Africa) to both the mRNA vaccines, in vitro data @BioNTech_Group/@Pfizer and @moderna_tx. Less vaccine efficacy vs B.1.351 has been confirmed in clinical trials for 3 vaccines https://t.co/2N7eKDllso [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1362160675913568256

  4. Jan 2021
    1. それを実践しているのが、全国に200店舗以上の大型スーパーマーケット「TRIAL」を展開するトライアルホールディングスだ

      TRIALはいつも先進技術に積極的に取り込んでいる

    1. Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., Berghmans, P.-J., Kimmel, M., Van Damme, P., de Hoon, J., Smith, W., Stephenson, K. E., De Rosa, S. C., Cohen, K. W., McElrath, M. J., … Schuitemaker, H. (2021). Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMoa2034201

  5. Dec 2020
    1. Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Collins, A. M., Colin-Jones, R., Cutland, C. L., Darton, T. C., Dheda, K., Duncan, C. J. A., … Zuidewind, P. (2020). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)32661-1

  6. Nov 2020
    1. “Let’s say a trial is listed and I have to cross examine a witness,” he said. “Now, what is the guarantee that the witness would be willing to go all the way to the court in such a time?” If witnesses do not appear, then the matter would merely be adjourned.

      access to justice

  7. Oct 2020
  8. Sep 2020
    1. Siemieniuk, R. A., Bartoszko, J. J., Ge, L., Zeraatkar, D., Izcovich, A., Kum, E., Pardo-Hernandez, H., Rochwerg, B., Lamontagne, F., Han, M. A., Liu, Q., Agarwal, A., Agoritsas, T., Chu, D. K., Couban, R., Darzi, A., Devji, T., Fang, B., Fang, C., … Brignardello-Petersen, R. (2020). Drug treatments for covid-19: Living systematic review and network meta-analysis. BMJ, 370. https://doi.org/10.1136/bmj.m2980

  9. Aug 2020
    1. Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., Wu, S.-P., Wang, Z., Wu, X.-H., Xu, J.-J., Zhang, Z., Jia, S.-Y., Wang, B.-S., Hu, Y., Liu, J.-J., … Chen, W. (2020). Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)31605-6

    1. Horby, P., Mafham, M., Linsell, L., Bell, J. L., Staplin, N., Emberson, J. R., Wiselka, M., Ustianowski, A., Elmahi, E., Prudon, B., Whitehouse, A., Felton, T., Williams, J., Faccenda, J., Underwood, J., Baillie, J. K., Chappell, L., Faust, S. N., Jaki, T., … Landray, M. J. (2020). Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. MedRxiv, 2020.07.15.20151852. https://doi.org/10.1101/2020.07.15.20151852

  10. Jul 2020
    1. Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S. P., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fonter-Garfias, C., Shi, P.-Y., Tuereci, O., Tompkins, K. R., Walsh, E. E., … Jansen, K. U. (2020). Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. MedRxiv, 2020.06.30.20142570. https://doi.org/10.1101/2020.06.30.20142570